Skip to main content
Oncolys BioPharma Inc. logo

Oncolys BioPharma Inc. — Investor Relations & Filings

Ticker · 4588 ISIN · JP3202170001 T Manufacturing
Open in API
Filings indexed 83 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country JP Japan
Listing T 4588

About Oncolys BioPharma Inc.

https://www.oncolys.com/en/

Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research and development of breakthrough therapies and diagnostics for cancer. The company's core technology is oncolytic virotherapy, which utilizes viruses to selectively target and destroy cancer cells. Its development pipeline addresses multiple stages of cancer care, spanning from early detection and prognostic testing to loco-regional and systemic treatments. The company aims to develop innovative and effective drugs to meet the needs of patients and healthcare providers in the field of oncology.

Recent filings

Filing Released Lang Actions
腫瘍溶解ウイルスOBP-301の新たな適応での治験届提出に関するお知らせ
Regulatory Filings Classification · 65% confidence The document is a Japanese press release by Oncolys Biopharma (code 4588) announcing the submission of a Phase1b/2a clinical trial notification for their oncolytic virus OBP-301 to the PMDA. It contains no financial statements, earnings figures, AGM materials, management changes, or regulatory filings of a financial nature. It is a general corporate/regulatory announcement that does not fit other specific categories. Therefore, it falls under the 'Regulatory Filings' fallback category (RNS).
2026-06-03 Japanese
腫瘍溶解ウイルスOBP-301の欧州での内視鏡投与に関する特許付与予定通知発行のお知らせ
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing the anticipated grant of a patent in Europe for a tumor-lysing virus. It does not contain financial statements, votes, insider transactions, or any other specific filing content. It’s a general regulatory announcement that doesn’t fit other categories, so it falls under Regulatory Filings (RNS).
2026-05-27 Japanese
腫瘍溶解ウイルス テロメライシン注の製造販売承認に関する薬事審議会 再生医療等製品・生物由来技術部会結果のお知らせ
Regulatory Filings Classification · 90% confidence The document is a corporate announcement regarding the Japanese Ministry of Health’s Pharmaceuticals and Medical Devices Agency deliberation outcome and approval process for a drug (Telomelysin injection). It contains no financial statements, shareholder voting, capital changes, management changes, or meeting materials. It is a regulatory/business disclosure that does not fit any specific financial report category. Therefore, it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-22 Japanese
腫瘍溶解ウイルスOBP-301の新たな特許査定に関するお知らせ
Legal Proceedings Report Classification · 86% confidence The document is a public announcement by Oncolys BioPharma Co. regarding a new patent allowance (a divisional application) for its tumor-lysing virus OBP-301. It does not contain financial results, governance changes, or calls for shareholder votes. Instead, it reports a legal matter (patent prosecution outcome), fitting the definition of a Legal Proceedings Report. Therefore, the correct classification is LTR.
2026-05-18 Japanese
腫瘍溶解ウイルスOBP-301のIOVC2026発表に関するお知らせ
Regulatory Filings
2026-04-30 Japanese
腫瘍溶解ウイルスOBP-301のファストトラック指定に関するお知らせ
Regulatory Filings
2026-04-23 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.